Zymeworks (ZYME) Net Income towards Common Stockholders (2021 - 2026)

Zymeworks (ZYME) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$44.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 95.1% year-over-year to -$44.2 million; the trailing twelve-month figure through Mar 2026 stood at -$102.7 million (up 9.7% YoY), and the FY2025 full-year result was -$81.1 million, up 33.88% from the prior year.
• Net Income towards Common Stockholders declined to -$44.2 million in Q1 2026, from -$41.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $309.4 million in Q4 2022 to a low of -$72.6 million in Q1 2022.
• A 5-year average of -$14.3 million and a median of -$29.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 890.33% in 2022 and slumped 104.68% in 2023, its largest moves.
• Tracing ZYME's Net Income towards Common Stockholders over 5 years: stood at $309.4 million in 2022, then tumbled by 104.68% to -$14.5 million in 2023, then plunged by 62.31% to -$23.5 million in 2024, then tumbled by 75.31% to -$41.2 million in 2025, then declined by 7.17% to -$44.2 million in 2026.
• Business Quant data shows ZYME's Net Income towards Common Stockholders at -$44.2 million in Q1 2026, -$41.2 million in Q4 2025, and -$19.6 million in Q3 2025.